[HTML][HTML] Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims …
A Boster, J Nicholas, N Wu, WS Yeh, M Fay… - Neurology and …, 2017 - Springer
Introduction Limited data are available on the real-world effectiveness of newer oral disease-
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh, M Fay… - Neurology and …, 2017 - go.gale.com
Introduction Limited data are available on the real-world effectiveness of newer oral disease-
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh, M Fay… - Neurology and …, 2017 - europepmc.org
Methods Patients newly-initiating DMF, interferon beta (IFNβ), glatiramer acetate (GA),
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh, M Fay… - Neurology and …, 2017 - infona.pl
Introduction Limited data are available on the real-world effectiveness of newer oral disease-
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh… - Neurology and …, 2017 - pubmed.ncbi.nlm.nih.gov
Introduction Limited data are available on the real-world effectiveness of newer oral disease-
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
[HTML][HTML] Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh, M Fay… - Neurology and …, 2017 - ncbi.nlm.nih.gov
Methods Patients newly-initiating DMF, interferon beta (IFNβ), glatiramer acetate (GA),
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, W Yeh, M Fay… - Neurology and …, 2017 - search.proquest.com
Methods Patients newly-initiating DMF, interferon beta (IFN [beta]), glatiramer acetate (GA),
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh… - Neurology & …, 2017 - search.ebscohost.com
Introduction: Limited data are available on the real-world effectiveness of newer oral disease-
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh… - Neurology and …, 2017 - ohiostate.elsevierpure.com
Introduction: Limited data are available on the real-world effectiveness of newer oral disease-
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to …
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims …
A Boster, J Nicholas, N Wu, WS Yeh, M Fay… - Neurology and …, 2017 - europepmc.org
Methods Patients newly-initiating DMF, interferon beta (IFNβ), glatiramer acetate (GA),
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …
teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial …